Navigation Links
XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Date:8/19/2007

VALLEY COTTAGE, New York, August 15 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the acquisition, development and commercialization of therapeutics for the treatment of unmet medical needs, particularly neuropathic pain and hepatitis C, today announced its financial results for the six months ended June 30, 2007.

At June 30, 2007, the Company had cash, cash equivalents and short-term bank deposits of $12.6 million, compared to $25.2 million at December 31, 2006. The decrease of $12.6 million during the first six months of 2007 was attributable primarily to the Company's $7.5 million upfront payment made in connection with the in-licensing of Bicifadine in January 2007, operating expenditures associated with the planned Phase IIb clinical trial of Bicifadine, the development of the DOS hepatitis C pre-clinical program, and operating expenditures associated with the Company's legacy hepatitis C clinical programs that were terminated this year.

The loss for the six months ended June 30, 2007 was $14.6 million, or $0.07 per ordinary share, compared to a loss of $7.3 million, or $0.04 per ordinary share, for the six months ended June 30, 2006, representing an increase in net loss of $7.3 million. The increased loss was primarily attributable to the $7.5 million upfront payment in connection with the in-licensing of Bicifadine and additional costs associated with the Bicifadine program, offset by lower costs associated with the Company's legacy hepatitis C clinical programs. The increase in loss was also due to a $0.6 million charge that was recorded relating to stock appreciation rights granted as part of the Bicifadine transac in operating assets and

liabilities:

Decrease (increase) in other receivables

and prepaid expenses 5 38 (604)

Increase in accounts payable and

accrued expenses 132 449 3,049

Increase (decrease) in deferred gain (200) (200) 597

--------- --------- --------

Net cash used in operating activities (13,022) (5,671) (113,609)

--------- --------- --------

CASH FLOWS FROM INVESTING ACTIVITIES:

Decrease (increase) in short-term deposits 10,660 -- (10,185)

Decrease (increase) in restricted deposits 121 (5) (44)

Investment in investment securities -- -- (3,363)

Proceeds from sales of investment securities -- -- 3,773

Proceeds from sales of trading securities 54 -- 54

Employee severance pay funds (6) (12) (915)

Purchase of property and equipment (47) (16) (4,089)

Proceeds from disposals of

property and equipment 288 33 540

Acquisition in respect of license and

purchase of assets -- -- (548)

--------- --------- --------

Net cash provided by (used in) investing

activities 11,070 -- (14,777)

--------- --------- --------

Interim Consolidated Statements of Cash Flows

for the Six Months Ended June 30, 2007 and 2006 (unaudited)(continued)

(in thousands of US dollars)

Period from

Six months March 9, 1993(*)

ended June 30, to June 30,

2007 2006 2007

---------- ---------- ----------

CASH FLOWS FROM FINANCING ACTIVITIES:

Issuance of share capital - net of share

issuance expenses -- 24,391 128,734

Exercise of share warrants and stock

options 3 92 2,103

Proceeds from long-term debt -- -- 399

Proceeds from short-term debt -- -- 50

Repayment of long-term debt -- -- (399)

Repayment of short-term debt -- -- (50)

--------- --------- ---------

Net cash provided by financing activities 3 24,483 130,837

--------- --------- ---------

NET INCREASE (DECREASE) IN CASH AND

CASH EQUIVALENTS (1,949) 18,812 2,451

BALANCE OF CASH AND CASH EQUIVALENTS AT

BEGINNING OF PERIOD 4,400 13,360 --

--------- --------- ---------

BALANCE OF CASH AND CASH EQUIVALENTS AT

END OF PERIOD 2,451 32,172 2,451

======== ========= =========

Supplementary information on investing

and financing activities not involving

cash flows -

Issuance of ordinary shares in respect of

license, and purchase of assets -- -- 1,391

Conversion of convertible subordinated

Debenture into shares -- -- 1,700

Supplemental disclosures of cash flow

information:

Income taxes paid 166 63 623

======== ========= =========

Interest paid -- -- 350

======== ========= =========

(*) Incorporation date see note 1.

XTL Biopharmaceuticals Ltd.

(A Development Stage Company)

Notes to Interim Consolidated Financial Statements

as of June 30, 2007 unaudited)

1. GENERAL

XTL Biopharmaceuticals Ltd. (the "Company") was incorporated under the Israel Companies Ordinance on March 9, 1993. The Company is a development stage company in accordance with Statement of Financial Accounting Standards ("SFAS") No. 7 "Accounting and Reporting by Development Stage Enterprises."

Through June 30, 2007, the Company has incurred losses in an aggregate amount of US $129.6 million. Such losses have resulted from the Company's activities as a development stage company. It is expected that the Company will be able to finance its operations from its current reserves through 2007. Continuation of the Company's current operations after utilizing its current cash reserves is dependent upon the generation of additional financial resources either through agreements for the commercialization of its product portfolio or through external financing. These matters raise substantial doubt about the Company's ability to continue as a going concern.

The Company has not generated any revenues from its planned principal operations and is dependent upon significant financing to provide the working capital necessary to execute its business plan. If the Company determines that it is necessary to seek additional funding, there can be no assurance that the Company will be able to obtain any such funding on terms that are acceptable to it, if at all.

2. STOCK-BASED COMPENSATION

The Company accounts for equity instruments issued to employees and directors in accordance with Statement of Financial Accounting Standards ("SFAS") No. 123R "Share - Based Payment" ("SFAS 123R"). SFAS 123R addresses the accounting for share-based payment transactions in which a company obtains employee services in exchange for (a) equity instruments of a company or (b) liabilities that are based on the fair value of a company's equity instruments or that may be settled by the issuance of such equity instruments. SFAS 123R requires instead that such transactions be accounted for using the grant-date fair value based method.

The Company accounts for equity instruments issued to third party service providers (non-employees) in accordance with the fair value method prescribed by SFAS 123R, and the provisions of Emerging Issues Task Force Issue ("EITF") No. 96-18, "Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling Goods or Services" ("EITF 96-18").

The Company accounts for the transaction advisory fee in the form of stock appreciation rights in accordance with the provisions of EITF 96-18 and by the provisions of EITF No. 00-19, "Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock" ("EITF 00-19").

3. RESEARCH AND DEVELOPMENT COSTS

Research and development costs are expensed as they are incurred and consist primarily of salaries and related personnel costs, fees paid to consultants and other third-parties for clinical and laboratory development, license and milestone fees, and facilities-related and other expenses relating to the design, development, testing, and enhancement of product candidates.

In connection with the purchase of assets, amounts assigned to intangible assets to be used in a particular research and development project that have not reached technological feasibility and have no alternative future use are charged to in-process research and development costs at the purchase date.

Contact:

Ron Bentsur, Chief Executive Officer

Tel: +1-845-267-0707 ext. 225

+972-8-930-4444

tion. For the six months ended June 30, 2007 and 2006, the Company's loss of $14.6 million and $7.3 million, respectively, included $1.0 million and $1.2 million, respectively, of non-cash stock option compensation expense.

Ron Bentsur, Chief Executive Officer of XTL, commented, "From a financial standpoint our spend over the first 6 months, excluding the extraordinary payment associated with the in-licensing of Bicifadine, was slightly below plan. We have been planning our Phase IIb study for Bicifadine in diabetic neuropathic pain and are looking forward to starting that study shortly. As a member of the SNRI class, a proven class in neuropathic pain, and as a drug candidate that has demonstrated anti-pain activity in multiple clinical trials, we believe that Bicifadine represents a very compelling later-stage opportunity." Mr. Bentsur added, "We are very excited about the pending commencement of the Phase IIb clinical study for Bicifadine as we strive to increase investor awareness to this undervalued opportunity."

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future financial performance, clinical and business prospects for our clinical compound for neuropathic pain, Bicifadine, and for our pre-clinical compounds for hepatitis C from our XTL-DOS program, growth and operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to start a clinical trial with Bicifadine in 2007 and our ability to successfully complete cost-effective pre-clinical trials for our DOS program, both of which will directly impact our ability to continue to fund our operations; our ability to meet anticipated development timelines for all of our drug candidates due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission and the London Stock Exchange, including our annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2007. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.xtlbio.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

XTL BIOPHARMACEUTICALS LTD.

(A Development Stage Company)

Consolidated Balance Sheets as of June 30, 2007 and 2006

(unaudited), and December 31, 2006 (audited)

(in thousands of US dollars, except share amounts)

June 30, December 31,

2007 2006 2006

---------- ---------- ----------

A s s e t s

CURRENT ASSETS:

Cash and cash equivalents 2,451 32,172 4,400

Short-term bank deposits 10,185 -- 20,845

Trading securities -- -- 102

Property and equipment

(held for sale) -- net 35 43 18

Deferred tax asset -- -- 29

Other receivables and prepaid expenses 651 644 702

--------- --------- ---------

Total current assets 13,322 32,859 26,096

--------- --------- ---------

EMPLOYEE SEVERANCE PAY FUNDS 42 173 98

RESTRICTED LONG-TERM DEPOSITS 53 119 172

PROPERTY AND EQUIPMENT -- net 128 620 490

INTANGIBLE ASSETS -- net 18 32 25

DEFERRED TAX ASSET -- -- 19

--------- --------- ---------

T o t a l assets 13,563 33,803 26,900

========= ========= =========

Liabilities and shareholders' equity

CURRENT LIABILITIES:

Accounts payable and accrued expenses 3,130 2,705 3,003

Deferred gain 399 399 399

Other current liabilities 565 -- --

--------- --------- ---------

Total current liabilities 4,094 3,104 3,402

--------- --------- ---------

LIABILITY IN RESPECT OF EMPLOYEE

SEVERANCE OBLIGATIONS 188 444 340

DEFERRED GAIN 198 598 398

COMMITMENTS AND CONTINGENCIES

--------- --------- ---------

Total liabilities 4,480 4,146 4,140

--------- --------- ---------

SHAREHOLDERS' EQUITY:

Ordinary shares of NIS 0.02 par value

(authorized 300,000,000 as of June

30, 2007, June 30, 2006 and

December 31, 2006, issued and

Outstanding 220,154,349,

220,069,801 and 220,124,349 as of

June 30, 2007, June 30, 2006 and

December 31, 2006, respectively) 1,072 1,072 1,072

Additional paid in capital 137,583 135,667 136,611

Deficit accumulated during the

development stage (129,572) (107,082) (114,923)

--------- --------- ---------

Total shareholders' equity 9,083 29,657 22,760

--------- --------- ---------

Total liabilities and shareholders'

equity 13,563 33,803 26,900

========= ========= =========

Interim Consolidated Statements of Operations for the Six

Months Ended June 30, 2007 and 2006 (unaudited)

(in thousands of US dollars, except share and per share amounts)

Period from

Six months ended March 9, 1993(*)

June 30, to June 30,

2007 2006 2007

----------- ----------- -----------

REVENUES:

Reimbursed out-of-pocket expenses -- -- 6,012

License 227 227 1,320

---------- ---------- ---------

227 227 7,332

COST OF REVENUES:

Reimbursed out-of-pocket expenses -- -- 6,012

License (with respect to

royalties) 27 27 167

----------- ----------- ---------

27 27 6,179

GROSS MARGIN 200 200 1,153

----------- ----------- ---------

RESEARCH AND DEVELOPMENT COSTS

(includes non-cash stock option

compensation of $66 and $107,

for the six months ended

June 30, 2007 and 2006,

respectively) 12,118 5,008 105,237

L E S S - PARTICIPATIONS 56 -- 11,006

----------- ----------- ---------

12,062 5,008 94,231

IN-PROCESS RESEARCH AND

DEVELOPMENT COSTS -- -- 1,783

GENERAL AND ADMINISTRATIVE

EXPENSES (includes non-cash

stock option compensation of

$892 and $1,105, for the six

months ended June 30, 2007

and 2006, respectively) 2,523 2,532 37,111

BUSINESS DEVELOPMENT COSTS

(includes non-cash stock option

compensation of $11 and $1, for

the six months ended June 30,

2007 and 2006, respectively,

and also includes stock

appreciation rights compensation

of $565 for the six months ended

June 30, 2007) 828 168 5,982

----------- ----------- ---------

OPERATING LOSS 15,213 7,508 137,954

FINANCIAL AND OTHER INCOME, net 351 323 8,635

----------- ----------- ---------

LOSS BEFORE INCOME TAXES 14,862 7,185 129,319

INCOME TAXES (213) 106 253

----------- ----------- ---------

LOSS FOR THE PERIOD 14,649 7,291 129,572

----------- ----------- ---------

BASIC AND DILUTED LOSS PER $ 0.07 $ 0.04

ORDINARY SHARE

WEIGHTED AVERAGE NUMBER OF

SHARES USED IN COMPUTING BASIC

AND DILUTED LOSS PER ORDINARY

SHARE 220,145,233 183,085,938

----------- -----------

(*) Incorporation date see note 1.

Interim Consolidated Statements of Changes in Shareholders'

Equity for the Six Months Ended June 30, 2007 (unaudited)

(in thousands of US dollars, except share amounts)

Ordinary shares

-------------------- Additional

Number of paid in

shares Amount capital

----------- ------- -------

BALANCE AT DECEMBER 31, 2006 220,124,349 1,072 136,611

CHANGES DURING THE SIX MONTHS

ENDED JUNE 30, 2007:

Comprehensive loss - loss for

the period -- -- --

Non-employee stock option

compensation expenses -- -- 5

Employee stock option compensation

expenses -- -- 964

Exercise of stock options 30,000 (**) 3

----------- ------- --------

BALANCE AT JUNE 30, 2007 220,154,349 1,072 137,583

=========== ======= ========

Deficit

accumulated

during the

development

stage Total

--------- ---------

BALANCE AT DECEMBER 31, 2006 (114,923) 22,760

CHANGES DURING THE SIX MONTHS

ENDED JUNE 30, 2007:

Comprehensive loss - loss for the

period (14,649) (14,649)

Non-employee stock option

compensation expenses -- 5

Employee stock option compensation

expenses -- 964

Exercise of stock options -- 3

--------- ---------

BALANCE AT JUNE 30, 2007 (129,572) 9,083

========= =========

(**) Represents an amount less than $1,000.

Interim Consolidated Statements of Cash Flows

for the Six Months Ended June 30, 2007 and 2006 (unaudited)

(in thousands of US dollars)

Period from

Six months March 9, 1993(*)

ended June 30, to June 30,

2007 2006 2007

---------- ---------- ----------

CASH FLOWS FROM OPERATING ACTIVITIES:

Loss for the period (14,649) (7,291) (129,572)

Adjustments to reconcile loss to net cash

used in operating activities:

Depreciation and amortization 69 114 3,141

Linkage difference on restricted long-term (2) (4) (9)

deposits

Acquisition of in process research

and development -- -- 1,783

Gain on disposal of property and equipment (53) (25) (92)

Increase (decrease) in liability in

respect of employee severance obligations (49) 35 1,187

Impairment charges 95 -- 475

Gain from sales of investment securities -- -- (410)

Other income related to exchange of shares -- -- (100)

Loss from trading securities 48 -- 46

Stock option based compensation expenses 969 1,213 6,427

Stock appreciation rights compensation

expenses 565 -- 565

Gain on amounts funded in respect of

employee severance pay funds -- -- (92)

Deferred tax asset 48 -- --

Changes
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd

Copyright©2007 PR Newswire.

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Md. , Feb. 10, 2016  The Maryland ... Busch , has announced that University of Maryland School ... PhD, MBA and University of Maryland Medical System President ... of the "Speaker,s Medallion," the highest honor given to ... of Delegates. Dean Reece and Mr. ...
(Date:2/10/2016)... York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has ... develop new vaccines and immunotherapies for infectious diseases and cancer. , ...
(Date:2/10/2016)... -- Matchbook, Inc., a company specializing in procurement and ... today the appointment of Jim Shuman ... 25 years of experience in supply chain, logistics ... decades in executive level roles as the SVP ... most recently headed global logistics and procurement at ...
(Date:2/10/2016)... NY (PRWEB) , ... February 10, 2016 , ... LATHAM, ... packages at the SPIE Photonics West conference in San Francisco’s Moscone Center ... 14 in the same venue. , These latest InGaAs PIN diode standard packages ...
Breaking Biology Technology:
(Date:2/9/2016)... Calif. , Feb. 9, 2016 Vigilant Solutions ... license plate reader (LPR) to develop a lead in a ... commercially available LPR data to locate the suspect vehicle. Due ... of the case have been omitted at the agency,s request. ... for the agency explains, "Our victim was found deceased at ...
(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... the addition of the "Global Facial ... offering. --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has ... Facial Recognition Market 2016-2020" report to ... Markets ( http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ...
(Date:2/3/2016)... --> --> Fourth quarter ... up 1,187% compared with fourth quarter of 2014. Gross margin ... (loss: 30.0). Earnings per share increased to SEK 6.39 (loss: ... (neg: 74.7). , --> --> ... 2,900.5 M (233.6), up 1,142% compared with 2014. Gross margin ...
Breaking Biology News(10 mins):